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Purpose: To report novel transforming growth factor beta-induced (TGFBI) mutations responsible for lattice corneal
dystrophy (LCD), the associated genotype-phenotype correlation, and structural changes in the mutant proteins in three
Chinese families.
Methods: Three unrelated Chinese families were diagnosed as Type I LCD. Mutations in TGFBI were detected by
sequencing all of the 17 exons and splice sites of the gene. Phenotype, including corneal erosions, and opacification in
the families were compared. Structural changes of the mutant proteins were modeled. One hundred healthy volunteers
were recruited as controls for sequence analysis of TGFBI.
Results: Two novel mutations, c.(1702G>C and 1706T>A; p.Arg514Pro and Phe515Leu) in TGFBI were identified in
Family 1. Two known hotspot mutations, c. 531C>T (p. Arg124Cys) and c.1876A>G (p.His572Arg), were revealed in
Family 2 and Family 3, respectively. Sequence analysis in the 100 healthy control subjects, the unaffected members in
Family 1, and evolutionary alignment showed that the novel mutations occurred in the conserved amino acids. Structural
modeling revealed changes in the 2nd structure of the mutant proteins, but did not detect gross structural changes.
Mutations c.(1702G>C and 1706T>A; p.Arg514Pro and Phe515Leu) and the c. 531C>T (p. Arg124Cys) were present in
the corneas with sever opacification.
Conclusions: The novel mutations c.(1702G>C and 1706T>A; p.Arg514Pro and Phe515Leu), c. 531C>T (p. Arg124Cys),
c.1876A>G (p.His572Arg) in TGFBI were responsible for LCD in the 3 families. Mutations c.(1702G>C and 1706T>A)
(p.Arg514Pro and Phe515Leu) and the c. 531C>T (p. Arg124Cys) were associated with more severe LCD phenotypes in
the families. These results provide more data for molecular diagnosis and prognosis of the disease.
Lattice corneal dystrophy (LCD) is an inherited disease
characterized by the accumulation of amyloid materials that
form refractile lines and white dots in the corneal stroma.
Genetically,  this  disease  is  classified  into  five  distinct
subtypes, type I, II, III, and IIIA, and IV [1–3]. Patients usually
present with ocular pain and recurrent corneal erosions in the
first  or  second  decade  of  life.  Corneal  opacification  and
blindness could eventually occur, requiring keratoplasty to
restore sight. Type I LCD is the most common subtype and
the  disease  usually  progresses  slowly  [4].  These  clinical
findings  are  the  characteristics  of  LCD,  and  genetic
classification  does  not  really  reflect  them;  therefore,  a
classification that includes genetics and phenotype appears to
be more practical.
Genetically,  transforming  growth  factor  beta-induced
(TGFBI Entrez Gene ID: 7045) is the gene underlying most
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incidences of LCD. The dominant mode of inheritance has
been recognized as the pattern of transmission [5,6], although
homozygous  mutations,  for  the  severe  forms  of  corneal
dystrophy, and compound heterozygous mutations have been
reported [7]. To date more than 30 mutations of TGFBI are
responsible  for  corneal  dystrophy,  with  various  clinical
subtypes  being  identified  [7].  However,  no  structural
modeling of the mutant proteins has been reported. In this
paper, we report 2 novel mutations of TGFBI identified in one
Chinese family, two known heterozygous mutations in the
other two families, and genotype-phenotype correlation and
structural analysis of the four mutant proteins in the three
Chinese families with LCD.
METHODS
Patients and control subjects: Five members from Family 1,
four members from Family 2, one member from Family 3, and
one hundred healthy volunteers (Han ethnicity) in clinic of
Zhongshan Ophthalmic Center were recruited for this study.
This study was approved by the Review Board of Sun Yat-
Sen University. The principles outlined in the Declaration of
Helsinki, such as participant safety, clinical trial registration,
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224post-study  access,  usage  of  data  and  human  tissues,
compensating participants with research-related injury, were
followed. Pedigrees of the three families were constructed
(Figure 1). Among the three families, Family 1 and Family 2
came from Guangdong province, in the south of China, and
Family 3 came from Sichuan province, in Western China. All
three families are of Han ethnicity. Owing to the availability
of samples, ten members of the families were analyzed (III:2,
III:3, III:4, IV:2, IV:3 in Family 1; I:1, II:4, II:6, III:3 in Family
2; and II:2 in Family 3; Figure 1). No consanguinity between
the families was found in the family histories. Visual acuity,
slit lamp microscopy, and funduscopic examinations were
performed  by  ophthalmologists  (X.Z.  and  J.Y.).  Blood
samples were collected for DNA isolation. All the individuals
included in the study underwent clinical examination before
the  molecular  investigation.  Systemic  amyloidosis  was
excluded in all of the affected family members. One hundred
healthy volunteers (Han ethnicity) were recruited as controls
for sequence analysis of TGFBI. These control subjects were
free  of  corneal  opacity  and  epithelial  defect,  which  was
confirmed by slit-lamp microscopy.
Mutational  analysis:  Genomic  DNA  from  the  peripheral
blood of the available family members was extracted with a
QiaAmp  Kit  (Qiagen).  All  of  the  17  exons  and  flanking
intronic sequences of TGFBI (Entrez Gene ID: 7045) were
amplified by polymerase chain reaction (primer sequences
and PCR conditions are available on request). The products
were purified with a Pre-Sequencing Kit (USB, Cleveland,
OH)  and  sequenced  in  both  directions  using  a  BigDye
Terminator  v3.1  Cycle  Sequencing  Kit  and  an  ABI  3100
Genetic Analyzer (Applied Biosystems, Foster City, CA). The
results were compared with the sequence retrieved from the
UCSC  Genome  Browser.  The  HGVS  guidelines  for
describing  sequence  variations  and  numbering  were  used.
Haplotypes were constructed using the TGFBI locus markers
D5S816,  D5S393,  and  the  c.1702G>C  and  c.1706T>A
variants in Family 1.
Evolutionary comparisons of the TGFBI ortholog: The amino
acid  sequences  of  the  TGFBI  orthologs  of  chimpanzees
(ENSPTRG00000017264), dogs (ENSCAFG00000001091),
rats  (ENSRNOG00000012216),  mice
(ENSMUSG00000035493),  and  chicks
(ENSGALG00000006319) were retrieved from the Ensembl
Genome  Browser  and  compared  with  the  human  TGFBI
amino acid sequences (AAA61163.1).
Structural modeling of the wild and mutant proteins: The
SWISS MODEL was used to model the structure of the wild
type protein and the four mutant proteins. The 3D protein
models were viewed using RasMol. The secondary structures
were predicted by PredictProtein, NNPREDICT, and PROF
to obtain a comprehensive understanding of the effect of the
mutations found in the three families.
RESULTS
Clinical  findings:  All  of  the  affected  family  members
examined  showed  anterior  refractile  corneal  stromal
deposition  characterized  by  several  branching  and
nonbranching lattice figures resembling pipe stems in both
Figure 1. Pedigrees of Family 1, 2, and
3.  The  closed  symbols  represent
individuals affected by the LCD and the
open symbols represent those who are
unaffected.  Arrowheads  denote
probands. Asterisks point to members
analyzed in the study.
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225eyes. These patients also had delicate, filamentous, discrete,
short, and irregularly shaped stromal deposition, along with
corneal haze.
The onset of all the affected individuals in Family 1 was
in the second decade of life. Ocular pain, recurrent corneal
erosions,  and  corneal  opacification  were  the  frequent
complaints  and  clinical  signs  of  LCD.  These  symptoms
progressed  more  rapidly  in  relation  to  the  other  families.
Penetrating keratoplasty was necessary in the patients’ late
20s (Figure 2).
The proband (II-4) patient in Family 2 had visual loss in
both  eyes  when  she  was  approximately  23  years  old.  On
examination, subepithelial punctiform corneal erosions were
present in both eyes (Figure 3). In 1985, her father (I-1) had
penetrating keratoplasty for the first time on his right eye at
age 41. One year later, the corneal implant was rejected. He
had penetrating keratoplasty twice in both eyes one year later.
Due to recurrence of the primary disease, he had another
penetrating keratoplasty on his left eye ten years later (Figure
4). Unfortunately, his histopathological record could not be
retrieved. Her son (III-3) experienced a foreign body sensation
in both eyes, however, no abnormalities were found in his
corneas.
Family 2 was a branch of a large Chinese family of Han
ethnicity living in southern China. The family members with
LCD  encompass  five  generations.  Some  members  of  this
family were living overseas. We learned from the proband
(II-4)  that,  like  her,  some  members  of  the  family  had
analogous  symptoms  in  their  teenage  years,  and  some
members had undergone penetrating keratoplasty around age
40. However, we cannot find their medical records. We have
invited the other members of this family to our study, but have
yet to hear from them.
The proband (II-2) from Family 3 displayed thin linear
branching deposition in the subepithelial and stromal layers
in both eyes that first appeared during adulthood. The disease
progression  in  this  case  was  slow.  The  patient  also  had
recurrence of corneal erosions. No visual impairment was
found during examinations when he/she was 38 years old
(Figure 5).
Genetic  findings:  Pedigree  analysis  showed  an  autosomal
dominant inheritance pattern in all three families. In Family
1,  two  novel  mutations,  c.1702G>C  and  1706T>A
(p.Arg514Pro and Phe515Leu), in exon 11 of TGFBI (Figure
6) were identified in two of the patients (III-2 and III-4)
examined,  but  were  absent  in  the  4  unaffected  members
available for the analysis (III-3, IV-1, IV-2, and IV-3). In
Family  2,  a  known  hotspot  mutation,  c.  531C>T  (p.
Arg124Cys), in exon 4 was detected (Figure 7). A recently
reported mutation [8], c.1876A>G (p.His572Arg), in exon 13
was identified in the proband of Family 3 (Figure 8).
Sequence analysis of TGFBI in the 100 healthy control
subjects showed conserved c.1702G and c.1706T, suggesting
that  the  c.1702G>C  and  1706T>A  substitutions  were  not
polymorphisms.  Owing  to  the  lack  of  family  members,
haplotype analyses using the TGFBI locus markers D5S816
and D5S393 and the c.1702G>C and 1706T>A variants could
not conclusively identify parental origin of the two mutations.
Alignment of the amino acid sequences of TGFBI displayed
a high conservation of p.Arg514Pro and Phe515Leu in the
chimpanzee,  cow,  dog,  mouse,  rat,  chick,  and  Xenopus
orthologs (Figure 9).
Structural modeling: Prediction with the SWISS MODEL
indicated that all the mutations occurred in the alpha-helix
region, which, predictively, would induce local secondary
structure changes, although no gross structure modification
could be detected. In Family 1, the mutation p.Arg514Pro is
predicted to shorten the helix and induce the formation of a
downstream  turn  structure;  whereas  the  p.Phe515Leu
Figure 2. Thick lattice lines and a subepithelial clump resulting in reduced visual acuity as low as 20/200 in the 36-year-old man in Family 1
(III-4).
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226mutation could predictably elongate the helix. The combined
effects of these two mutations conformed to the result of
p.Arg514Pro.
DISCUSSION
In the present study, the affected individuals of Family 1 and
Family 2 had symptoms in the first decade of life; therefore,
penetrating keratoplasty is indicated in their late 20s. This
indicates  that  mutations  c.(1702G>C  and  1706T>A)
(p.Arg514Pro  and  Phe515Leu)  and  c.  531C>T  (p.
Arg124Cys) have more phenotypic effects. The mutation c.
1876A>G (p.His572Arg) is also identified in Family 3. The
proband of Family 3 has thin linear branching deposits in the
subepithelial  and  stromal  layers  in  both  eyes,  with  the
deposition detected in adulthood. Visual impairment was not
obvious in his/her 20s. The same mutation has been reported
in later onset Type I LCD [9] from a Thai family. Consistently,
the  average  age  of  onset  of  symptoms  of  the  affected
individuals in the Thai family was 28.6±8.1 years (range: 20–
50).  In  addition,  the  p.His572del  is  associated  with  a
unilateral, late-onset variant form of LCD in a 63-year-old
Figure  3.  The  affected  individual  of
Family 2 (II-4) at 28 years of age; a thin
lattice of deposition in the stromal layer
associated  with  subepithelial  smaller
opaque spots is shown.
Figure 4. Clinical photographs of corneas in one affected member (I-1) in Family 2 at 63 years of age. The right eye (A) contained opacifications
from presumed recurrent disease 20 years after a penetrating keratoplasty. The left eye (B) showed a corneal implant that was transparent after
a penetrating keratoplasty 10 years ago. This eye compounded with the primary cataract and the corrected visual acuity with pinhole is 20/32.
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227man  with  decreased  vision  in  the  affected  eye  [8].  This
indicates that c.1876A>G may be particularly associated with
the relatively late onset of LCD and a less severe phenotype.
Predominantly  expressed  by  the  corneal  epithelium,
TGFBI is believed to be an adhesion protein secreted into the
extracellular matrix and bound to Type I, II, and IV collagens
responsible for the structure of microfibrils and cell surface.
TGFBI is also a major gene responsible for most LCD cases.
To date, more than 30 mutations in TGFBI have been reported
to cause dominantly inherited corneal disorders [7], although
homozygous mutations are also reported in severe forms of
corneal  dystrophy  patients.  Moreover,  most  mutations
reported from present or previous studies are single base pairs
of  substitutions  affecting  one  of  the  alleles  in  the  locus.
Compound heterozygous mutations affecting both alleles are
rare.  Dighiero  and  colleagues  [10]  suggest  that  both
p.Arg124Leu  and  p.Thr125_Glu126del  compound
heterozygous mutations are responsible for the phenotype of
the family with granular corneal dystrophy. The compound
heterozygous  mutations  p.Arg124Cys  coupled  with
p.Gly470X (a nonsense mutation) have been identified in the
proband of one family [11]. However, the proband’s daughter
who carries the heterozygous mutation p.Gly470X alone was
unaffected.  This  raises  the  question  as  to  whether  the
p.Gly470X in the compound heterozygous mutations could be
pathogenic.  The  authors  speculated  that  the  p.Gly470X
Figure 5. The proband of Family 3(II-2)
at the 38 years of age with thin linear
irregular branching refractile lines and
white  dots  deposition  in  the
subepithelial and stromal layers. Visual
impairment was not obvious.
Figure 6. Sequencing results of the two
novel  mutations  c.1702G>C  and
1706T>A  (p.Arg514Pro  and
Phe515Leu) of TGFBI in Family 1, and
their corresponding normal sequences.
Arrows indicate the mutation positions.
Underlines  highlight  the  codons  that
contain the mutations.
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228nonsense mutation might be nonpathogenic or have a very low
penetrance.  The  third  compound  heterozygous  mutations,
p.Ala546Asp and p.Pro551Gln, have been reported in two
non-consanguineous African-American families [12].
In an attempt to distinguish the pathogenic mutations
from  polymorphism  in  the  compound  mutations  [12],
haplotype analysis of the TGFBI locus and sequenced samples
from  125  healthy  controls  show  no  common  haplotype
between the affected and unaffected family members and no
mutations in the control subjects. In this present study, 2 novel
mutations,  c.1702G>C  and  1706T>A  (p.Arg514Pro  and
Phe515Leu), are identified in Family 1. The two substituted
base pairs are only 4bp away from each other, and affect the
consecutive amino acids in the polypeptide. This also raises
the question whether the two mutations are located in one
allele consecutively, or in both alleles separately (one in each
of the alleles). These questions are unable to be answered due
to lack of sufficient family samples for the analysis. However,
the pedigree looks like a dominant inheritance in the family,
as the spouses (I:2, II:2) of the mutant affected members (I-1,
II-1) are unaffected. Regardless of whether the two mutations
occur  in  one  or  both  alleles,  the  pathogenic  roles  of  the
Figure  7.  Sequencing  results  of  the
heterozygote  mutation  c.  531C>T  (p.
Arg124Cys) of TGFBI in Family 2, and
their corresponding normal sequences.
Arrows indicate the mutation positions.
Underlines  highlight  the  codons  that
contain the mutations.
Figure  8.  Sequencing  results  of  the
heterozygote  mutations  c.1876A>G
(p.His572Arg) of TGFBI in Family 3,
and  their  corresponding  normal
sequences.  Arrows  indicate  the
mutation  positions.  Underlines
highlight  the  codons  that  contain  the
mutations.
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229mutations are likely associated with severity in the phenotype
of LCD, as they are absent in the unaffected family members
and  controls  subjects.  The  2nd  structural  changes  of  the
mutant protein by either one or both of the mutations also
provide  support  of  their  pathogenic  roles.  This  is  also
consistent with the phenotype severity in the family, as it has
an  earlier  age  of  onset,  relatively  faster  progression,  and
requires earlier penetrating keratoplasty compared to Family
3.
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